167 related articles for article (PubMed ID: 19945519)
1. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells.
Lim SH; Jeong YI; Moon KS; Ryu HH; Jin YH; Jin SG; Jung TY; Kim IY; Kang SS; Jung S
Int J Pharm; 2010 Mar; 387(1-2):209-14. PubMed ID: 19945519
[TBL] [Abstract][Full Text] [Related]
2. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
4. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of adriamycin-incorporated polymeric micelles of poly(gamma-benzyl L-glutamate)/poly(ethylene oxide).
Jeong YI; Na HS; Cho KO; Lee HC; Nah JW; Cho CS
Int J Pharm; 2009 Jan; 365(1-2):150-6. PubMed ID: 18786625
[TBL] [Abstract][Full Text] [Related]
8. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
9. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
10. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2.
Ren J; Shen S; Wang D; Xi Z; Guo L; Pang Z; Qian Y; Sun X; Jiang X
Biomaterials; 2012 Apr; 33(11):3324-33. PubMed ID: 22281423
[TBL] [Abstract][Full Text] [Related]
11. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
12. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.
Denora N; Laquintana V; Trapani A; Lopedota A; Latrofa A; Gallo JM; Trapani G
Mol Pharm; 2010 Dec; 7(6):2255-69. PubMed ID: 20958082
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro.
Jeong YI; Jin SG; Kim IY; Pei J; Wen M; Jung TY; Moon KS; Jung S
Colloids Surf B Biointerfaces; 2010 Aug; 79(1):149-55. PubMed ID: 20427160
[TBL] [Abstract][Full Text] [Related]
14. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells.
Kuo YC; Liang CT
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):131-7. PubMed ID: 21411296
[TBL] [Abstract][Full Text] [Related]
15. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin.
Kono K; Kojima C; Hayashi N; Nishisaka E; Kiura K; Watarai S; Harada A
Biomaterials; 2008 Apr; 29(11):1664-75. PubMed ID: 18194811
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model.
Aoki H; Kakinuma K; Morita K; Kato M; Uzuka T; Igor G; Takahashi H; Tanaka R
Int J Hyperthermia; 2004 Sep; 20(6):595-605. PubMed ID: 15370816
[TBL] [Abstract][Full Text] [Related]
17. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.
Lopez-Barcons LA; Polo D; Reig F; Fabra A
J Biomed Mater Res A; 2004 Apr; 69(1):155-63. PubMed ID: 14999763
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity.
Bachmeier BE; Nerlich AG; Lichtinghagen R; Sommerhoff CP
Anticancer Res; 2001; 21(6A):3821-8. PubMed ID: 11911253
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS
Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
